Profile of Graves Disease in a Tertiary Care Hospital
International Journal of Pharmaceutical Quality Assurance · 30.11.2026 · 17 (11)
DOI: 10.25258/ijpqa.17.11.2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmaceutical Quality Assurance, online erschienen am 30.11.2026. Verfasst von Aravind Reddy A. und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Graves’ disease is an autoimmune disorder characterized by excessive thyroid hormone production and is the most common cause of hyperthyroidism. It presents with diverse clinical manifestations and biochemical abnormalities. Early diagnosis and appropriate treatment are essential to achieve biochemical remission and prevent complications. This study evaluates the laboratory profile, treatment modalities, and outcomes of Graves’ disease in a tertiary care hospital.
Aim
To study the laboratory profile of Graves’ disease, compare different treatment modalities, and assess treatment outcomes in terms of achievement of euthyroid or hypothyroid states and disease relapse. Materials and Methods: An observational study was conducted over two years in the Department of General Medicine in collaboration with Biochemistry, Nuclear Medicine, and General Surgery. A total of 110 patients aged above 18 years with biochemical evidence of thyrotoxicosis and scintigraphically confirmed Graves’ disease were included. Patients with non-Graves’ thyrotoxicosis, pregnancy, or beta-blocker use were excluded. Clinical findings, hemoglobin levels, and thyroid function parameters were evaluated. Thyroid scintigraphy was performed using Technetium-99m pertechnetate. Treatment modalities included antithyroid drugs (ATD), radioactive iodine (RAI) therapy, and surgery. Treatment outcomes were assessed during follow-up.
Results
The most commonly affected age group was 40–59 years, with a female predominance and a male-tofemale ratio of 1:1.75. Weight loss (79.0%) and palpitations (72.7%) were the most common symptoms. Tremor (56.3%) was the predominant clinical finding. Serum TSH was below 0.005 IU/L in 98.1% of patients. Total T3 levels ranged from 2.1–4.0 ng/mL in 40% of patients, while total T4 levels ranged from 14.11–20.0 µg/dL in 40.9%. Of 104 treated patients, 47 received ATD, 54 underwent RAI therapy, and 3 underwent surgery. Among 45 patients followed up, 17 of 24 patients in the RAI group developed hypothyroidism by the third month. Three patients experienced persistent disease requiring further treatment.
Conclusion
Graves’ disease predominantly affects adults aged 40–59 years and is characterized by suppressed TSH and elevated thyroid hormone levels. RAI therapy was associated with a higher frequency of early hypothyroidism. Regular biochemical monitoring and individualized treatment are essential for achieving optimal outcomes.
Zitieren
APA
A., A. R., L., V., & Srikar, A. V. (2026). Profile of Graves Disease in a Tertiary Care Hospital. International Journal of Pharmaceutical Quality Assurance, 17(11). https://doi.org/10.25258/ijpqa.17.11.2
Vancouver
A. AR, L. V, Srikar AV. Profile of Graves Disease in a Tertiary Care Hospital. International Journal of Pharmaceutical Quality Assurance. 2026;17(11). doi:10.25258/ijpqa.17.11.2
BibTeX
@article{A2026,
author = {A., Aravind Reddy and L., Vyshali and Srikar, A. V.},
title = {Profile of Graves Disease in a Tertiary Care Hospital},
journal = {International Journal of Pharmaceutical Quality Assurance},
year = {2026},
volume = {17},
number = {11},
doi = {10.25258/ijpqa.17.11.2}
}
EUVIMED